Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
- PMID: 19923174
- PMCID: PMC2812355
- DOI: 10.1128/JVI.01482-09
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
Abstract
Induction of antibodies that neutralize a broad range of human immunodeficiency virus type 1 (HIV-1) isolates is a major goal of vaccine development. To study natural examples of broad neutralization, we analyzed sera from 103 HIV-1-infected subjects. Among progressor patients, 20% of sera neutralized more than 75% of a panel of 20 diverse viral isolates. Little activity was observed in sera from long-term nonprogressors (elite controllers). Breadth of neutralization was correlated with viral load, but not with CD4 count, history of past antiretroviral use, age, gender, race/ethnicity, or route of exposure. Clustering analysis of sera by a novel method identified a statistically robust subgrouping of sera that demonstrated broad and potent neutralization activity.
Figures



Similar articles
-
Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.J Gen Virol. 2012 Oct;93(Pt 10):2267-2278. doi: 10.1099/vir.0.043802-0. Epub 2012 Jul 12. J Gen Virol. 2012. PMID: 22791603
-
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11. J Virol. 2015. PMID: 25673728 Free PMC article.
-
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.J Virol. 2017 Sep 12;91(19):e00991-17. doi: 10.1128/JVI.00991-17. Print 2017 Oct 1. J Virol. 2017. PMID: 28747500 Free PMC article.
-
High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.J Gen Virol. 2010 Jan;91(Pt 1):250-8. doi: 10.1099/vir.0.015693-0. Epub 2009 Sep 30. J Gen Virol. 2010. PMID: 19793903 Free PMC article.
-
Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).Mol Med Rep. 2012 May;5(5):1311-7. doi: 10.3892/mmr.2012.790. Epub 2012 Feb 14. Mol Med Rep. 2012. PMID: 22344547 Clinical Trial.
Cited by
-
Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.AIDS Res Treat. 2012;2012:161584. doi: 10.1155/2012/161584. Epub 2012 May 27. AIDS Res Treat. 2012. PMID: 22693657 Free PMC article.
-
Broadly neutralizing antibodies and vaccine design against HIV-1 infection.Front Med. 2020 Feb;14(1):30-42. doi: 10.1007/s11684-019-0721-9. Epub 2019 Dec 19. Front Med. 2020. PMID: 31858368 Free PMC article. Review.
-
Broadly Neutralizing Antibodies against HIV: Back to Blood.Trends Mol Med. 2019 Mar;25(3):228-240. doi: 10.1016/j.molmed.2019.01.007. Epub 2019 Feb 18. Trends Mol Med. 2019. PMID: 30792120 Free PMC article. Review.
-
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14. Science. 2011. PMID: 21764753 Free PMC article.
-
Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth.J Virol. 2021 Aug 10;95(17):e0079721. doi: 10.1128/JVI.00797-21. Epub 2021 Aug 10. J Virol. 2021. PMID: 34160251 Free PMC article.
References
-
- Bailey, J. R., K. G. Lassen, H. C. Yang, T. C. Quinn, S. C. Ray, J. N. Blankson, and R. F. Siliciano. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80:4758-4770. - PMC - PubMed
-
- Beirnaert, E., P. Nyambi, B. Willems, L. Heyndrickx, R. Colebunders, W. Janssens, and G. van Der Groen. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J. Med. Virol. 62:14-24. - PubMed
-
- Binley, J. M., E. A. Lybarger, E. T. Crooks, M. S. Seaman, E. Gray, K. L. Davis, J. M. Decker, D. Wycuff, L. Harris, N. Hawkins, B. Wood, C. Nathe, D. Richman, G. D. Tomaras, F. Bibollet-Ruche, J. E. Robinson, L. Morris, G. M. Shaw, D. C. Montefiori, and J. R. Mascola. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668. - PMC - PubMed
-
- Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, and D. R. Burton. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous